# Locally Advanced Basal Cell Carcinoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/locally-advanced-basal-cell-carcinoma

> 2 upcoming FDA catalysts in locally Advanced Basal Cell Carcinoma: Libtayo® (cemiplimab, REGN) on Nov 2030 to Feb 2031 (topline data readout); Libtayo® (cemiplimab, REGN) on November 2030 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2030 to Feb 2031 | [Libtayo® (cemiplimab) topline data readout](https://sec-api.dev/pdufa/cemiplimab) | REGN | Locally Advanced Basal Cell Carcinoma | scheduled | "NCT07808515 (A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07808515)) |
| November 2030 | [Libtayo® (cemiplimab) primary completion](https://sec-api.dev/pdufa/cemiplimab) | REGN | Locally Advanced Basal Cell Carcinoma | scheduled | "NCT07808515 (A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2030-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07808515)) |

## Drugs

- [Libtayo® (cemiplimab)](https://sec-api.dev/pdufa/cemiplimab) (REGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/locally-advanced-basal-cell-carcinoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Locally Advanced Basal Cell Carcinoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/locally-advanced-basal-cell-carcinoma

```bibtex
@misc{secapidev_indications_locally_advanced_basal_cell_carcinoma_20261116,
  title        = {Locally Advanced Basal Cell Carcinoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/locally-advanced-basal-cell-carcinoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_locally_advanced_basal_cell_carcinoma_20261116","title":"Locally Advanced Basal Cell Carcinoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/locally-advanced-basal-cell-carcinoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
